本帖最后由 老马 于 2013-3-13 13:43 编辑 0 B$ C5 T1 d; a4 e" J4 d5 R( T* j
9 e$ F& b0 n, U* o健择（吉西他滨）+顺铂+阿瓦斯汀
/ v, I% p# }, _. S$ U Gemzar +Cisplatin + Avastin
: _' n; q! U$ ~3 ?http://annonc.oxfordjournals.org/content/21/9/1804.full
9 J' |5 `7 z( j d0 I |8 \7 hOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) , x' U0 S! d* {
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
$ t" ^! d3 {/ n+ ~! n9 o+ }/ uResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. & t7 i, P) W; D
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 799)
8 L0 z- Z1 f1 t4 [
华为网盘附件：. S$ D6 H: z! V. N4 m
【华为网盘】ava.JPG# `1 T$ F4 K9 K2 {3 f
|
显身卡
